In The News
Google’s ad tech dominance probed by second class action firm
Judge OKs cutting edge argument in $900M class action against CBA
Real estate listings giant REA accuses rival Domain of scraping its data
Allergan hit with class action over breast implants linked to cancer
Bayer launches High Court appeal to revive Xarelto patents
‘Replete with error’: Firm fights $5.4M security order in Macquarie class action
ATO understaffing to blame for tax dispute escalation, says new Dentons partner
Aurizon’s Flinders Logistics buy wins ACCC nod after deal restructure
ACCC accuses Webjet of misleading customers about flight prices, bookings
Firm fees, funder’s cut slashed in $180M stolen wages class action settlement
Please login to bookmarkClose

A second class action investigation against regenerative medicine company Mesoblast is underway, this one looking at claim it misled shareholders about the potential application of a developmental stem cell product to treat terminally-ill children.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au